COLUMBIA, Md., Jan 12, 2005 /PRNewswire-FirstCall via COMTEX/ -- Docosahexaenoic Acid (DHA), an omega-3 fatty acid, restores normal blood vessel function in children with inherited high cholesterol, according to results of a new study published in the December issue of The International Journal of Clinical Pharmacology and Therapeutics. The study concludes that restoration of normal blood vessel function has the "potential for preventing the progression of early coronary heart disease in high-risk children." The study used Martek DHA(TM), which is produced from microalgae.
"Our findings are the first to suggest that supplementation with DHA may improve vascular health in hyperlipidemic children at high risk for early heart disease," said Dr. Marguerite Engler, the study's lead investigator and professor at the University of California, San Francisco.
The study, funded by the National Institutes of Health, involved twenty children (between the ages of 9-19) with inherited high cholesterol. The children received Martek DHA(TM) supplements over one six week period and a placebo over another six week period. After the period in which they received the DHA, the children's blood vessel function improved significantly, demonstrating that DHA restores blood vessel function in children with high cholesterol to the levels reported in healthy children.
"The evidence continues to accumulate on the cardiovascular benefits of DHA for people of all ages," stated Henry "Pete" Linsert, Jr., Chairman and CEO of Martek. "This study clearly indicates that DHA played an important role in healthy blood vessel function in the children in this study."
Developed by a process that extracts DHA from algae under tightly controlled manufacturing conditions, Martek DHA(TM) is free of chemical pollutants and toxins that may be present in certain fish oils. Martek DHA(TM) is available to consumers through Neuromins(R) DHA.
Martek Biosciences Corporation (MATK) develops and sells products from microalgae. The Nutritional Products Group manufactures and sells two nutritional fatty acids, docosahexaenoic acid (DHA) and arachidonic acid (ARA). Martek has patented its DHA (DHASCO(R)) and ARA (ARASCO(R)) oil blend (Formulaid(R)) and sells it to infant formula manufacturers worldwide. Martek also sells its DHA oil, under the Neuromins(R) brand name, to the nutritional supplement industry, either directly or through a number of supplement manufacturers. The Fluorescent Products Group develops and sells a series of proprietary and non-proprietary fluorescent markers. These markers have been designed for use in a wide range of drug discovery and research applications.
This press release contains forward-looking statements regarding Martek's products. Such statements involve risks and uncertainties that could cause future actual results to differ due to a variety of risk factors, including without limitation those factors set forth in Martek's filings with the Securities and Exchange Commission.